Business Context and Reporting Period
Company: DaVita Health Care Partners Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 4, 2016
Subject: Regulation FD Disclosure regarding the final 2017 Medicare Advantage benchmark payment rates issued by the Centers for Medicare and Medicaid Services (CMS).
Key Financial Metrics and Impact
This filing does not report historical revenue, profit, cash flow, or debt figures. It provides a forward-looking estimate regarding the impact of new government rates on the Health Care Partners (HCP) business segment:
- Estimated Rate Reduction: Approximately 1% for DaVita's HCP business.
- Estimated Financial Impact: A net reduction of approximately $25 million to 2017 operating income.
- Industry Comparison: The industry average rate increase is approximately 0.85%, making DaVita's decline significant relative to peers.
Material Changes and Drivers
The estimated decline in Medicare Advantage rates for DaVita is more severe than the industry average due to two primary factors:
- Geographic Mix: A higher concentration of Medicare Advantage patients in counties receiving lower-than-average benchmark rate increases.
- Risk Model Revision: A higher-than-average impact from CMS revisions to the risk model designed to differentiate payment levels between dual-eligible and non-dual-eligible patients.
The final financial impact may vary based on the growth of HCP's patient volumes across markets and the specific benefit plan designs submitted to CMS.
Outlook, Risks, and Contingencies
Management Commentary: The company notes that the final impact is subject to variability based on patient volume growth and plan designs. The filing includes extensive forward-looking statements regarding risks to future performance.
Key Risks Identified:
- Downward pressure on commercial payor rates and potential loss of patients.
- Reductions in government payment rates under Medicare End Stage Renal Disease and other programs.
- Impact of the CMS Medicare Advantage benchmark structure.
- Legal compliance risks, including adherence to the Corporate Integrity Agreement (CIA) and ongoing government investigations.
- Increased competition from other dialysis providers and new care models (e.g., accountable care organizations).
- Risks related to the integration and operation of the HCP business, including employee retention and network disruptions.
Investor Verification Checklist
- Verify the final 2017 operating income impact once patient volume growth and benefit plan designs are finalized.
- Monitor the specific geographic distribution of HCP's Medicare Advantage patients to understand exposure to low-benchmark counties.
- Review the status of the Corporate Integrity Agreement (CIA) and any updates on government investigations.
- Assess the competitive landscape for commercial payor contracts and potential shifts in physician affiliation models.
- Track the integration progress of the HCP business and any associated operational disruptions.